{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sriprasart T"],"funding":["GSK"],"pagination":["133-158"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9859883"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["40(1)"],"pubmed_abstract":["<h4>Introduction</h4>Short-acting β<sub>2</sub>-agonist (SABA) reliever overuse is common in asthma, despite availability of inhaled corticosteroid (ICS)-based maintenance therapies, and may be associated with increased risk of adverse events (AEs). This systematic literature review (SLR) and meta-analysis aimed to investigate the safety and tolerability of SABA reliever monotherapy for adults and adolescents with asthma, through analysis of randomized controlled trials (RCTs) and real-world evidence.<h4>Methods</h4>An SLR of English-language publications between January 1996 and December 2021 included RCTs and observational studies of patients aged ≥ 12 years treated with inhaled SABA reliever monotherapy (fixed dose or as needed) for ≥ 4 weeks. Studies of terbutaline and fenoterol were e"],"journal":["Advances in therapy"],"pubmed_title":["Safety of SABA Monotherapy in Asthma Management: a Systematic Review and Meta-analysis."],"pmcid":["PMC9859883"],"funding_grant_id":["Study ID 218222"],"pubmed_authors":["Roguska A","Aggarwal B","Levy G","Sriprasart T","Garcia G","Mittal L","Rubin A","Fulmali S","Phansalkar A","Waterer G","Andrade MAL","Martin A"],"additional_accession":[]},"is_claimable":false,"name":"Safety of SABA Monotherapy in Asthma Management: a Systematic Review and Meta-analysis.","description":"<h4>Introduction</h4>Short-acting β<sub>2</sub>-agonist (SABA) reliever overuse is common in asthma, despite availability of inhaled corticosteroid (ICS)-based maintenance therapies, and may be associated with increased risk of adverse events (AEs). This systematic literature review (SLR) and meta-analysis aimed to investigate the safety and tolerability of SABA reliever monotherapy for adults and adolescents with asthma, through analysis of randomized controlled trials (RCTs) and real-world evidence.<h4>Methods</h4>An SLR of English-language publications between January 1996 and December 2021 included RCTs and observational studies of patients aged ≥ 12 years treated with inhaled SABA reliever monotherapy (fixed dose or as needed) for ≥ 4 weeks. Studies of terbutaline and fenoterol were e","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2025-04-06T09:47:05.066Z","creation":"2025-04-06T09:47:05.066Z"},"accession":"S-EPMC9859883","cross_references":{"pubmed":["36348141"],"doi":["10.1007/s12325-022-02356-2"]}}